Search all trials

Find therapies in clinical trials near you – page 4

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Breast cancer

Not recruiting

InvestigationalNo placebo

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study of DCC-3116 with Sotorasib, Binimetinib, and Trametinib for Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dcc-3116

Contact Research Centre

Breast cancer+2

Not recruiting

Registered drugNo placebo

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Hormone receptor positive breast cancer+1

Not recruiting

Registered drugNo placebo

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Fulvestrant

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Abemaciclib

Contact Research Centre

Breast cancer

Not recruiting

Registered drugNo placebo

Study on the Safety and Antitumor Activity of ARV-471 and Ribociclib in Adults with ER+ Advanced or Metastatic Breast Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Ribociclib

Contact Research Centre

Hormone receptor positive breast cancer+1

Not recruiting

Registered drugNo placebo

Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Antipsychotics

Contact Research Centre

Non-small cell lung cancer metastatic

Not recruiting

Registered drugNo placebo

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Inhibitor Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Docetaxel

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study on Datopotamab Deruxtecan and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer After Osimertinib Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Find therapies in clinical trials near you – page 4

46 trials match your criteria

Breast cancer

Study of Trastuzumab Deruxtecan for Patients with Unresectable or Metastatic HER2-low or HER2 IHC0 Breast Cancer

Non-small cell lung cancer

Study of DCC-3116 with Sotorasib, Binimetinib, and Trametinib for Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations

Breast cancer+2

Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Hormone receptor positive breast cancer+1

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Breast cancer

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Hormone receptor positive HER2 negative breast cancer

Study of Capivasertib with CDK4/6 Inhibitors and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer

Breast cancer

Study on the Safety and Antitumor Activity of ARV-471 and Ribociclib in Adults with ER+ Advanced or Metastatic Breast Cancer

Hormone receptor positive breast cancer+1

Study Comparing Sacituzumab Govitecan with Other Treatments for Patients with HR+/HER2- Metastatic Breast Cancer After Endocrine Therapy

Non-small cell lung cancer metastatic

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Inhibitor Treatment

Non-small cell lung cancer

Study on Datopotamab Deruxtecan and Osimertinib for Patients with Advanced Non-Small Cell Lung Cancer After Osimertinib Treatment

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.